Welcome to our dedicated page for SBC Medical Group Holdings Incorporated news (Ticker: SBC), a resource for investors and traders seeking the latest updates and insights on SBC Medical Group Holdings Incorporated stock.
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) is frequently featured in financial and industry news as a global provider of consulting and management services to medical corporations and their clinics. News coverage of SBC often focuses on its expansion in aesthetic medicine, its multi-brand clinic strategy, and its capital markets activity as a Nasdaq-listed company included in the Russell 3000 Index.
Readers following SBC Medical news can expect updates on international expansion initiatives, such as partnerships and consulting agreements in markets like Thailand and Singapore, and strategic moves in the United States. Recent announcements include a strategic minority equity investment and collaboration framework with OrangeTwist, a U.S.-based MedSpa chain, marking SBC’s formal entry into the U.S. medical aesthetics market. News also covers partnerships with regional operators like BLEZ ASIA in Thailand, where SBC provides management support and clinical protocol guidance for new dermatology-focused clinics.
Another major category of SBC news involves corporate and capital strategy. The company issues press releases on quarterly financial results, including revenue trends, operating income, EBITDA, and key operating metrics such as the number of franchise locations and customer visits. SBC also reports on its capital strategy, including the effectiveness of a shelf registration statement on Form S-3 and authorization of a share repurchase program, as well as its inclusion in major equity indexes.
In addition, SBC news highlights strategic investments and acquisitions, such as tender offers for shares of Waqoo, Inc., a regenerative medicine-focused research and development company. These transactions are presented as part of SBC’s broader plan to enhance its healthcare technology capabilities and support long-term growth in aesthetic and related medical fields. Investors and observers can use this news feed to monitor SBC’s clinic network growth, international partnerships, and financial performance over time.
SBC Medical Group Holdings (NASDAQ: SBC) reported its Q2 2025 financial results, showing significant year-over-year declines across key metrics. Total revenue decreased 18% to $43 million, while net income fell 87% to $2.5 million. EPS dropped to $0.02 from $0.20 in Q2 2024.
The company's strategic restructuring initiatives included discontinuing its staffing business, completing targeted divestitures, and revising its fee structure. Despite the financial downturn, SBC Medical expanded its franchise network to 259 locations and served 6.31 million customers in the last twelve months, achieving a 72% customer repeat rate.
For H1 2025, total revenues were $91 million (down 16% YoY), with net income of $24 million (down 36% YoY) and EBITDA of $40 million (down 25% YoY).
SBC Medical (NASDAQ:SBC), a global aesthetic clinic services provider, has scheduled its Q2 2025 financial results announcement for August 13, 2025, before U.S. market opening. The company will host a conference call at 8:30 AM ET on the same day to discuss results and take questions.
Participants must pre-register through the provided link to access the conference call viewing site, which will feature presentation materials 10 minutes before the call. The presentation replay will remain accessible until August 13, 2026, with materials available for download on the company's IR website.
SBC Medical Group (Nasdaq: SBC) has acquired MB career lounge, a Japanese provider of management support services for medical institutions, through a cash transaction. The deal includes JUN CLINIC, a network of aesthetic clinics across multiple Japanese locations including Shirokane, Ginza, and Nagano.
The acquisition strengthens SBC Medical's position in Japan's growing aesthetic medicine market, which reached ¥631 billion in 2024 with 6.2% year-over-year growth. JUN CLINIC, known for its personalized treatment approach including laser therapies and injectables, operates under board-certified dermatologist supervision and serves as a certified facility for the Customized Treatment Study Group.
This strategic move aims to accelerate regional expansion, diversify service offerings, and reduce reliance on single procedures or geographical areas.
SBC Medical (NASDAQ:SBC) has appointed renowned plastic and craniofacial surgeon Dr. Steven R. Cohen as Medical Strategy Advisor to accelerate its global expansion initiatives. Dr. Cohen, founder of Faces+ and recognized by Newsweek as one of "America's Best Plastic Surgeons," brings over 30 years of clinical experience and significant innovations in regenerative aesthetics.
Following its Nasdaq listing in September 2024, SBC Medical aims to leverage Dr. Cohen's expertise to enhance medical quality, strengthen international brand positioning, expand academic collaborations, and improve physician training programs. Dr. Cohen, a Clinical Professor at UC San Diego, is known for inventing the internal craniofacial distraction device and LipoCube, which have become global industry standards.
SBC Medical Group Holdings (NASDAQ: SBC), a global aesthetic clinic services provider, has appointed Shinya Inoue as its new Chief Marketing Officer (CMO), effective July 1, 2025. In his role, Inoue will focus on enhancing the brand value of the group's portfolio, including Shonan Beauty Clinic, and optimizing the company's marketing infrastructure with an emphasis on digital innovation.
Inoue brings extensive experience from prominent companies including P&G Japan, Eli Lilly Japan, Adobe, and KDDI. Most recently, he served as CMO at Pioneer Corporation, where he led marketing organization initiatives and new product launches. His expertise spans brand strategy, organizational management, and integrated digital marketing.
The appointment follows SBC Medical's Nasdaq listing last year and aligns with the company's mission to make aesthetic medicine more accessible since opening its first clinic in Fujisawa in 2000.
SBC Medical Group Holdings (NASDAQ: SBC), a global aesthetic clinic services provider, has been added to the Russell 3000® Index effective June 30, 2025. This inclusion automatically places SBC Medical in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, along with corresponding growth and value style indexes.
The Russell indexes are significant benchmarks used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against them as of June 2024. FTSE Russell has also announced plans to transition to semi-annual reconstitution starting in 2026 to maintain accurate market representation.
SBC Medical Group Holdings (Nasdaq: SBC), a global aesthetic clinic services provider, has announced its participation in four upcoming investor events in May and June 2025. The company will conduct presentations and hold one-on-one investor meetings at:
1. Lytham Partners Spring 2025 Virtual Investor Conference (May 29)
2. Noble Capital Markets' Emerging Growth Virtual Equity Conference (June 5)
3. Sidoti Small-Cap Virtual Conference (June 11)
4. Zacks SCR Life Sciences Virtual Investor Forum (June 12)
Each event will feature a company webcast presentation, with opportunities for investors to schedule individual meetings with management through the respective conference platforms.